



Commercial PA Criteria
Effective: October 13, 2023

Prior Authorization: Akeega (niraparib and abiraterone acetate)

Products Affected: Akeega (niraparib and abiraterone acetate) capsules

Medication Description: Akeega is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a cytochrome P450 (CYP)17 inhibitor, indicated with prednisone for the treatment of deleterious or suspected deleterious BReast CANcer (BRCA)-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) in adults.

Covered Uses: AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

Exclusion Criteria:

1. None

Required Medical Information:

1. Diagnosis
2. Medical history

Prescriber Restriction: The medication is prescribed by or in consultation with an oncologist

Age Restriction: 18 years and older

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

1. **Prostate Cancer.** Approve if the patient meets the following (A, B, C, D, **AND** E):

- A. Patient is ≥ 18 years of age; **AND**
- B. Patient has metastatic castration-resistant prostate cancer; **AND**
- C. Patient has a BReast CANcer (BRCA) mutation; **AND**
- D. The medication is used in combination with prednisone; **AND**
- E. Patient meets one of the following (i **OR** ii):
 - i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog; **OR**
Note: Examples are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix acetate subcutaneous injection), and Orgovyx (relugolix tablets).
 - ii. Patient has had a bilateral orchiectomy.

September 2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

References:

1. Akeega™ tablets [prescribing information]. Horsham, PA: Janssen; August 2023.
2. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 4.2023 – September 7, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on September 27, 2023.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/13/2023